Company Information and Disclosure Statement

Section One: Issuers' Annual Disclosure Obligations for the For Period Ended December 31, 2015

Viratech Corp.

OTCPK: VIRA

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

Exact Company Name: Viratech Corp. (hereinafter referred to as “we”, “us”, or “our” or “the Issuer”).
Name used by predecessor entities in the past five years: Imperia Entertainment, Inc. until 10-2011

2) Address of the issuer's principal executive offices

Company Headquarters
429 W. Plumb Lane
Reno, NV 89509
Phone: 209-477-3030
Email:
Website: www.viratech.org

IR Contact
None

3) Security Information

Trading Symbol: VIRA
Common Stock Outstanding: 754,143,750 (as of 12/31/2015)
Restricted Common Stock: 668,687,689(as of 12/31/2015)
Preferred Stock Outstanding: 3,882,500 (as of 12/31/2015)
CUSIP Number: 927647 107
Par or Stated Value: Common-$.0001 and Preferred stock-$0.0001
Total shares authorized: Common – Two billion (2,000,000,000) shares. Preferred – Twenty million (20,000,000) shares designated to two classes as of 12/31/2015
Total shares outstanding: 758,026,250 as of 12/31/2015

Transfer Agent:
Standard Registrar and Transfer Co.
12528 S. 1840 E.
Draper UT 84020
801-571-8844
Registered Under Exchange Act: Yes
Regulatory Authority: Security Exchange Commission (SEC)

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months:

None

4) Issuance History

A. The nature of each offering (e.g., Securities Act Rule 504, interstate, etc.);

B. Any jurisdiction where the offering was registered or qualified;
C. The number of shares offered;
D. The number of shares sold;
E. The price at which the shares were offered, and the amount actually paid to the issuer;
F. The trading status of the shares; and
G. Whether the certificates or other documents that evidence the shares contain legend (1) stating that the shares have registered under the Securities Act (2) setting forth or referring to the restrictions on transferability and sales of the share under the Securities Act.

Shareholder	Jurisdiction	Date	# of Shares Sold	Price Per share	Dollar Amount Sold	Nature of Offering
Various(a)	United States	10/01/2014	300,000	$.01	$3,000	Cash

(a) Two individuals.

With respect to private offering of securities, the list shall also indicate the identity of the person who purchased securities in such private offering; provided, however, that in the event that any such person is an entity, the list shall also indicate (a) the identity of each natural person beneficially owning, directly or indirectly, more than ten percent (10%) of any class of equity securities of such entity and (b) to the extent not otherwise disclosed, the identity of each natural person who controlled or directed, directly or indirectly, the purchase of such securities for such entity.

5) Financial Statements

The following documents are included as part of a separate Disclosure:

Financial Statements of the Company as of December 31, 2015 and 2014 and for the years ended December 31, 2015 and 2014:

Balance Sheet;
Statement of Income;
Statement of cash flows;
Financial notes; and
Audit letter, if audited
Notes to Financial Statements

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

Viratech is an open source biotechnology development company engaged in the business of researching and developing cancer treatment protocols through the use of open source web based research networks.

B. Date and State (or Jurisdiction) of Incorporation:

The Company was originally incorporated in 2000, in the state of California. The Company has been a Nevada corporation since July 18, 2006.

C. the issuer's primary and secondary SIC codes;

Primary Code: 8071 Medical Laboratories

Secondary Code: 7379 Computer Related Services, Not Elsewhere Classified

D. the issuer's fiscal year end date;

December 31

E. principal products or services, and their markets;

Viratech is an open source biotechnology development company engaged in the business of researching and developing cancer treatment protocols through the use of open source web based research networks.

.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company leases offices at 429 W. Plumb Lane, Reno, NV 89509. The lease is held by the Company's CEO/CFO and he does not charge the Company for use of any space.

8) Officers, Directors, and Control Person

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the name of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement:

Fred Schiemann, CEO/President/CFO

Person Named above owns 0 shares of Common stock. Mr. Schiemann is currently negotiating an employment agreement, which will include shares of Common Stock of the Company.

Kevin Buckman, MD, Chief Medical Officer

Person Named above owns 600,000,000 shares of Common Stock and 3,500,000 shares of Preferred Stock.

Valerie Kidd Bishop, Treasurer/Director

Person Named above owns 1,850,000 shares of Common stock.

Aziz Kamali, Secretary/Director

Person Named above owns 0 shares of Common stock.

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

   None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

   None

C. Beneficial Shareholders. provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. if any of the beneficial shareholders are corporate shareholders,

provide the name and address of the person(s) owning or controlling such corporate shareholders and the residents agents of the corporate shareholders.

Kevin Buckman

Individual Named above owns 600,000,000 shares of Common Stock.
Individual Named above owns 3,500,000 shares of Class B Preferred Convertible Stock.
Kevin Buckman, Chief Executive Officer owned 79.56% of its Common Stock.
4719 Quail Lakes Dr., Suite G319, Stockton, CA 95207

Therefore with the 3,500,000 shares of Class B Convertible Preferred Stock Mr. Buckman owns as an individual, he owns 775,000,000 shares of the Company's Common Stock, or 81.75% of the issued and outstanding common stock.

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matter relating to operations, business development and disclosure:

Legal Counsel
Crawford Shaw
230 Park Avenue, 10th Floor
New York, NY 10169
(917) 453-9986

Accountant or Auditor
Fred Schiemann
429 W. Plumb Lane
Reno Nevada 89509
(775) 830-3663
fschiemann@yahoo.com

Investor Relations Consultant
None

Other Advisor
Name:
Firm:
Address 1
Address 2
Phone
Email

10) Issuer Certification

The issuer shall include certifications but the chief executive officer and chief financial officer of the issuer (or any other person with different title, but having the same responsibilities).

I, Fred Schiemann, certify that:

1. I have reviewed this Annual Disclosure Statement of Viratech Corp.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 30, 2016

/s/ Fred Schiemann
CEO/President/CFO